Caxton Associates LP acquired a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,797 shares of the medical research company's stock, valued at approximately $590,000.
Other institutional investors also recently bought and sold shares of the company. Strategic Financial Concepts LLC bought a new position in shares of Bio-Rad Laboratories in the fourth quarter worth about $3,561,000. Lecap Asset Management Ltd. purchased a new stake in Bio-Rad Laboratories in the 4th quarter worth approximately $510,000. Diversified Trust Co bought a new stake in Bio-Rad Laboratories during the 4th quarter worth approximately $958,000. DAVENPORT & Co LLC lifted its holdings in Bio-Rad Laboratories by 48.8% during the fourth quarter. DAVENPORT & Co LLC now owns 84,677 shares of the medical research company's stock valued at $27,817,000 after purchasing an additional 27,780 shares in the last quarter. Finally, Principal Financial Group Inc. increased its stake in shares of Bio-Rad Laboratories by 95.6% in the third quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company's stock worth $14,836,000 after purchasing an additional 21,669 shares in the last quarter. 65.24% of the stock is owned by institutional investors.
Bio-Rad Laboratories Price Performance
Shares of Bio-Rad Laboratories stock opened at $231.69 on Wednesday. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 12 month low of $215.38 and a 12 month high of $387.99. The stock has a 50 day moving average of $245.53 and a 200 day moving average of $303.44. The firm has a market cap of $6.49 billion, a PE ratio of -3.56 and a beta of 1.00.
Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported $2.54 EPS for the quarter, beating analysts' consensus estimates of $1.73 by $0.81. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. The firm had revenue of $585.40 million during the quarter, compared to the consensus estimate of $573.01 million. During the same period in the prior year, the company earned $2.30 EPS. The company's quarterly revenue was down 4.2% compared to the same quarter last year. On average, research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of research analysts recently weighed in on BIO shares. StockNews.com cut shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Monday, February 17th. UBS Group lowered their price objective on Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Citigroup cut their target price on Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Royal Bank of Canada lowered their price target on Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Finally, Wells Fargo & Company reduced their price objective on shares of Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Bio-Rad Laboratories presently has a consensus rating of "Moderate Buy" and an average price target of $327.40.
Check Out Our Latest Research Report on Bio-Rad Laboratories
About Bio-Rad Laboratories
(
Free Report)
Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
Featured Articles
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bio-Rad Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.
While Bio-Rad Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
